466 related articles for article (PubMed ID: 18974239)
1. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.
Richir MC; Bouwman RH; Teerlink T; Siroen MP; de Vries TP; van Leeuwen PA
JPEN J Parenter Enteral Nutr; 2008; 32(6):613-21. PubMed ID: 18974239
[TBL] [Abstract][Full Text] [Related]
2. The clinical significance of asymmetric dimethylarginine.
Siroen MP; Teerlink T; Nijveldt RJ; Prins HA; Richir MC; van Leeuwen PA
Annu Rev Nutr; 2006; 26():203-28. PubMed ID: 16848705
[TBL] [Abstract][Full Text] [Related]
3. The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature.
Visser M; Paulus WJ; Vermeulen MA; Richir MC; Davids M; Wisselink W; de Mol BA; van Leeuwen PA
Eur J Heart Fail; 2010 Dec; 12(12):1274-81. PubMed ID: 20923854
[TBL] [Abstract][Full Text] [Related]
4. Homocysteine increases the production of asymmetric dimethylarginine in cultured neurons.
Selley ML
J Neurosci Res; 2004 Jul; 77(1):90-3. PubMed ID: 15197741
[TBL] [Abstract][Full Text] [Related]
5. Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule.
Fliser D
Eur J Clin Invest; 2005 Feb; 35(2):71-9. PubMed ID: 15667575
[TBL] [Abstract][Full Text] [Related]
6. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
Yamagishi S; Ueda S; Okuda S
Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
[TBL] [Abstract][Full Text] [Related]
7. Dimethylarginine dimethylaminohydrolase (DDAH)--a critical regulator of hypertensive left ventricular hypertrophy?
Bai Y; Hui R
Med Hypotheses; 2008; 70(5):962-6. PubMed ID: 17983707
[TBL] [Abstract][Full Text] [Related]
8. Liver plays a central role in asymmetric dimethylarginine-mediated organ injury.
Ferrigno A; Di Pasqua LG; Berardo C; Richelmi P; Vairetti M
World J Gastroenterol; 2015 May; 21(17):5131-7. PubMed ID: 25954086
[TBL] [Abstract][Full Text] [Related]
9. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.
Böger RH
J Nutr; 2004 Oct; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
Böger RH
Cardiovasc Res; 2003 Oct; 59(4):824-33. PubMed ID: 14553822
[TBL] [Abstract][Full Text] [Related]
11. Asymmetric dimethylarginine in children with homocystinuria or phenylketonuria.
Kanzelmeyer N; Tsikas D; Chobanyan-Jürgens K; Beckmann B; Vaske B; Illsinger S; Das AM; Lücke T
Amino Acids; 2012 May; 42(5):1765-72. PubMed ID: 21472412
[TBL] [Abstract][Full Text] [Related]
12. [Asymmetric dimethylarginine: metabolism, arginine paradox, pathophysiology].
Gilinskiĭ MA
Usp Fiziol Nauk; 2007; 38(3):21-39. PubMed ID: 17977229
[TBL] [Abstract][Full Text] [Related]
13. GC-MS assay for hepatic DDAH activity in diabetic and non-diabetic rats by measuring dimethylamine (DMA) formed from asymmetric dimethylarginine (ADMA): evaluation of the importance of S-nitrosothiols as inhibitors of DDAH activity in vitro and in vivo in humans.
Chobanyan K; Thum T; Suchy MT; Zhu B; Mitschke A; Gutzki FM; Beckmann B; Stichtenoth DO; Tsikas D
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 858(1-2):32-41. PubMed ID: 17825631
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule.
De Gennaro Colonna V; Bianchi M; Pascale V; Ferrario P; Morelli F; Pascale W; Tomasoni L; Turiel M
Med Sci Monit; 2009 Apr; 15(4):RA91-101. PubMed ID: 19333216
[TBL] [Abstract][Full Text] [Related]
15. Role of dimethylarginine dimethylaminohydrolase activity in regulation of tissue and plasma concentrations of asymmetric dimethylarginine in an animal model of prolonged critical illness.
Davids M; Richir MC; Visser M; Ellger B; van den Berghe G; van Leeuwen PA; Teerlink T
Metabolism; 2012 Apr; 61(4):482-90. PubMed ID: 22000584
[TBL] [Abstract][Full Text] [Related]
16. The DDAH/ADMA/NOS pathway.
Tran CT; Leiper JM; Vallance P
Atheroscler Suppl; 2003 Dec; 4(4):33-40. PubMed ID: 14664901
[TBL] [Abstract][Full Text] [Related]
17. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase.
Murray-Rust J; Leiper J; McAlister M; Phelan J; Tilley S; Santa Maria J; Vallance P; McDonald N
Nat Struct Biol; 2001 Aug; 8(8):679-83. PubMed ID: 11473257
[TBL] [Abstract][Full Text] [Related]
18. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism.
Wilcken DE; Sim AS; Wang J; Wang XL
Mol Genet Metab; 2007 Aug; 91(4):309-17; discussion 308. PubMed ID: 17560156
[TBL] [Abstract][Full Text] [Related]
19. Gene transfer of dimethylarginine dimethylaminohydrolase-2 improves the impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells induced by lysophosphatidylcholine.
Feng M; Liu L; Guo Z; Xiong Y
Eur J Pharmacol; 2008 Apr; 584(1):49-56. PubMed ID: 18342305
[TBL] [Abstract][Full Text] [Related]
20. Asymmetric dimethylarginine and critical illness.
Brinkmann SJ; de Boer MC; Buijs N; van Leeuwen PA
Curr Opin Clin Nutr Metab Care; 2014 Jan; 17(1):90-7. PubMed ID: 24281375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
